Simplifying Thromboprophylaxis Could Improve Outcomes in Orthopaedic Surgery by Friedman, Richard J.
Hindawi Publishing Corporation
Thrombosis
Volume 2010, Article ID 108049, 5 pages
doi:10.1155/2010/108049
Review Article
SimplifyingThromboprophylaxisCould Improve
Outcomesin Orthopaedic Surgery
Richard J. Friedman
Department of Orthopaedic Surgery, Roper Hospital, Charleston Orthopaedic Associates, 1012 Physicians Drive,
Charleston, SC 29414, USA
Correspondence should be addressed to Richard J. Friedman, rjfriedman@mybones.com
Received 6 February 2010; Revised 27 May 2010; Accepted 18 August 2010
Academic Editor: Bergqvist Bergqvist
Copyright © 2010 Richard J. Friedman. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Venous thromboembolism is a serious complication after total hip or knee surgery, and there is a well-established clinical need for
thromboprophylaxis. However, in a large number of cases adequate administration of thromboprophylaxis does not seem to occur
after total joint arthroplasty. A major challenge in the management of thromboprophylaxis is to balance the beneﬁts of treatment
with the risks, including bleeding complications. Another potential barrier to the optimal use of thromboprophylaxis could be the
inconvenience of currently available agents. Many surgeons therefore adopt a conservative approach towards thromboprophylaxis.
Simplifying therapy with more convenient, eﬃcacious, and safe anticoagulants could change attitudes to anticoagulant use and
improve adherence to thromboprophylactic guidelines.
1.Introduction
Venous thromboembolism (VTE) is a serious complication
aftermajororthopaedicsurgery[1].Theratesofvenographic
deep vein thrombosis (DVT) and proximal DVT 7 to 14 days
after major orthopaedic surgery in patients who receive
no thromboprophylaxis are approximately 40% to 60%
and 10% to 30%, respectively [1]. The manifestation of
DVT is, to some extent, a consequence of bone damage
during surgery, when procoagulant debris triggers thrombin
generation,resultinginhypercoagulability[2].Inadditionto
hypercoagulability, the other components of Virchow’s triad
of venous stasis and endothelial damage are also thought to
playapartinthrombosis[3].Thus,thereisawell-established
clinical need for thromboprophylaxis after arthroplasty [1].
A major challenge in the management of anticoagulants
is to balance the beneﬁts of treatment with the risks,
including bleeding complications. Many surgeons appear
concerned about postoperative bleeding and tend to adopt
a conservative approach towards the relative risks and
beneﬁts of thromboprophylaxis [2]. Consequently, although
evidence-based guidelines and recommendations advocate
the use of anticoagulants after major orthopaedic surgery,
thromboprophylaxis is still used suboptimally [4–6]. How-
ever, the evidence that careful prophylaxis administered at
an appropriate time after surgery causes surgical bleeding
is sparse [7]. In this paper, current trends in thrombopro-
phylaxis after orthopaedic surgery in the United States (US)
are described. Factors limiting appropriate implementation
of thromboprophylaxis regimens are also discussed.
2. CurrentStandardof Care
Further to the consensus document developed by the
National Institute of Health in 1986 [8], there have been
a series of American College of Chest Physicians (ACCP)
guidelines published on the use of pharmacological agents
for thromboprophylaxis after total hip arthroplasty (THA)
and total knee arthroplasty (TKA), last updated in 2008 [1].
In the US, the available options for anticoagulation
and thromboprophylaxis after elective THA or TKA are
the vitamin K antagonists (VKAs, e.g., warfarin), the low-
molecular-weight heparins (LMWHs), and fondaparinux
(an indirect Factor Xa inhibitor). Each of these options is
associated with signiﬁcant limitations that complicate use2 Thrombosis
in clinical practice. VKAs have been the mainstay of oral
anticoagulant therapy for more than 60 years [9]. However,
VKAs have unpredictable pharmacokinetics and pharmaco-
dynamics and signiﬁcant inter- and intrapatient variability
in dose-response relationships. They are associated with
multiple drug-drug and food-drug interactions and have a
narrow therapeutic window [9]. Regular coagulation moni-
toring is therefore required to ensure that the international
normalized ratio is within the recommended range of 2.0
to 3.0. The heparins are administered subcutaneously, which
means that patients often require daily appointments or
a nurse visit to administer their medication. LMWHs are
also associated with the risk of developing heparin-induced
thrombocytopenia [10]. Fondaparinux is also administered
subcutaneouslyandiscontraindicatedinpatientswithsevere
renal impairment and in those that weigh less that 50kg. In
patientsovertheageof75whohaveundergoneTHAorTKA,
fondaparinux causes an increased risk of bleeding [11].
The timing of initiation of prophylaxis depends upon the
type of anticoagulant used. Warfarin therapy is generally ini-
tiated prior to surgery because of its delayed onset of action
whereasprophylaxiswithLMWHcanbestarted10–12hours
before or 12–24 hours after surgery. There does not seem to
be a clear advantage with either regimen, and both regimens
are recommended by the ACCP [1]. Thromboprophylaxis
is recommended to continue for at least 10 days after joint
replacement surgery, with extended prophylaxis for up to
35 days recommended for those patients undergoing THA
surgery and with a suggestion that thromboprophylaxis for
up to 35 days could be beneﬁcial for those undergoing TKA
[1].Traditionally,thromboprophylaxisusedtocontinueonly
until the patient was discharged from hospital [12] despite
thefactthatthiscouldbeasuboptimal duration[13]andthe
riskofDVTandmortalityafterdischargeisconsiderable[14,
15].ThemedianlengthofstayinUShospitalsisnowasshort
as3daysafterTHAand4daysafterTKA[16].Aretrospective
study of the medical records of 3,778 orthopaedic surgery
patients found that 88% were discharged from hospital and
prescribed warfarin or acetylsalicylic acid [6].
3.SuboptimalUtilization of
Thromboprophylaxis
Despite the fact that thromboprophylaxis is now rec-
ommended for routine use after total joint arthroplasty,
it is not always used optimally. Approximately 10% of
patients received inadequate in-hospital thromboprophy-
laxis, and approximately 33% received inadequate postdis-
charge thromboprophylaxis according to ﬁndings from the
US Hip and Knee Registry (1996–2001) [17]. An analysis of
thedatafromthemultinationalGlobalOrthopaedicRegistry
(GLORY) to evaluate the compliance of surgeons with the
ACCP guidelines for the prevention of VTE showed that only
47% of THA patients and 61% of TKA patients received
prophylaxis in accordance with the recommended start time,
duration, and dose/treatment intensity recommended by
the guidelines [16]. Although nearly all patients received
prophylaxis on the ﬁrst day after surgery, more than a
quarter did not receive any form of prophylaxis 7 days after
surgery [18].
Suboptimal thromboprophylaxis decreases patient out-
comes, resulting in many patients remaining at unnecessary
risk of thrombosis and its complications [4]. The reasons for
lack of compliance with the guidelines may be numerous.
They include lack of awareness, poor understanding or
disagreement with guidelines (either speciﬁcally or as a
general concept), resistance to changing established prac-
tices, and doubt that a new approach will change outcomes.
Established surgeons may also be reluctant to use new anti-
coagulant regimens because of a fear of increased bleeding
risk [17]. Attitudes may also limit a physician’s willing-
ness to follow guidelines. An awareness of the guidelines
does not necessarily mean that physicians have suﬃcient
knowledge to critically evaluate and apply recommendations
[4].
Otherpotentialbarriersincludethemistakenbeliefthata
small asymptomatic DVT is not important because it cannot
cause clinically signiﬁcant pulmonary embolism (PE) [19],
which fortunately is only held by a minority [20]. Due to the
often clinically silent nature of VTE, and the low incidence of
VTEduringtheshortpostoperativehospitalstay,thechances
of a surgeon witnessing a major DVT or an acute PE are rare
[4]. In addition, the trend towards earlier hospital discharge
means that many symptomatic events occur after that time
[21, 22], and patients are often seen by other specialists when
referred back to hospital with a venous thromboembolic
event; therefore, surgeons are often unaware of the true
incidence of VTE in their patients.
Long-term sequelae of VTE are frequent and often
disabling [23]. Recurrent VTE can occur after surgery
although the incidence is less than in other patients groups
such as those with cancer [24]. Thrombosis damages the
deep venous valves resulting in venous reﬂux and venous
hypertension of the lower limbs. This residual venous
obstruction and inﬂammation are thought to be responsible
for the development of postthrombotic syndrome [25, 26].
Chronic thrombotic pulmonary hypertension, which is
associatedwithconsiderablemorbidityandmortality,occurs
in approximately 3%-4% of patients over 2 years after a
symptomatic PE [27].
4. Economic Impact of
VenousThromboembolism
The acute and chronic phases of VTE-related care have
substantial economic consequences [28, 29] that can be
eﬀectively modeled [30]. A recent study found that the total
annual healthcare cost for a VTE ranged from $7,594 to
$16,644, depending on the type of event and whether it was
a primary or secondary diagnosis. The hospital readmission
ratesforDVTorPEwithin12monthswere5.3%forprimary
and 14.3% for secondary diagnoses [31]. These data indicate
that thromboprophylaxis with anticoagulants should not
only be beneﬁcial to patients but could also be cost eﬀective
for the healthcare system [32, 33].Thrombosis 3
5. Need for MoreConvenientAnticoagulants
Another potential barrier to the optimal use of thrombopro-
phylaxis could be the inconvenience of currently available
agents [34]. Orthopaedic surgeons and their patients would
beneﬁt from an oral anticoagulant that could be adminis-
t e r e di nﬁ x e dd o s e s[ 35].
6. Simplifying Therapy
Noncompliance can result in a poor quality of life and
increased medical expenditures in managed care. In a study
of diabetic patients, total medical costs were approximately
$4,500 for patients at 80%–100% adherence compared with
approximately $8,900 for those at 1%–19% adherence [36].
A variety of factors aﬀect noncompliance, but simplifying
treatment has been shown to improve adherence in asthma
patients [37], and cardiovascular patients given single-pill
amlodipine/atorvastatin were found to be approximately
three times more likely to achieve adherence over 1 year
of followup than patients given a two-pill regimen [38].
Similarly, simplifying therapy to a once-daily regimen in
virologically suppressed HIV-1-infected patients improved
adherence and patient satisfaction [39].
7.Novel Anticoagulants
Anticoagulants in development are targeting diﬀerent steps
in the coagulation pathway to provide simpler alternatives
to currently available anticoagulants. Among these new
agents are direct thrombin inhibitors and direct Factor Xa
inhibitors [40]. The direct thrombin inhibitor dabigatran
etexilate appears an attractive alternative to the current
standard of care in patients after THA and TKA [41–44]. It
has been granted marketing authorization in the European
Union and Canada for the prevention of VTE after THA
or TKA. The manufacturer’s recommended dose is 220mg
once daily (starting 1–4 hours after surgery with a single
110mg capsule) for a total of 28–35 days after THA or a
t o t a lo f1 0d a y sa f t e rT K A[ 45]. Direct Factor Xa inhibitors
in development include rivaroxaban, apixaban, edoxaban
(DU-176b), and YM150, and of these rivaroxaban is in the
most advanced stage of development [46]. Rivaroxaban has
shown potential as a once-daily, oral anticoagulant that may
be administered in ﬁxed doses for the prevention and treat-
ment of thromboembolic disorders following orthopaedic
surgery [47–52]. Rivaroxaban is approved in more than
90 countries worldwide, including the European Union and
Canada, for the prevention of VTE after elective hip or knee
replacement surgery in adult patients. A dose of 10mg once
daily(withtheinitialdose6–10hoursaftersurgery,provided
that haemostasis has been achieved) for 5 weeks after elective
hip arthroplasty or 2 weeks after elective knee arthroplasty is
recommended by the manufacturer [53].
The main diﬀerence between direct thrombin inhibitors
and direct Factor Xa inhibitors is their mechanism of action.
They also diﬀer in their pharmacokinetic and pharmacody-
namic proﬁles, such as metabolism. For example, in the case
of dabigatran, more than 80% of the systemically available
drug is eliminated by renal excretion [54]. Two-thirds
of administered rivaroxaban are metabolized to inactive
metabolites(halfofthisiseliminatedviathekidneysandhalf
via the fecal route), and one-third is excreted as unchanged
active drug in the urine [55].
8. Conclusion
The need to use thromboprophylaxis after major ortho-
paedic surgery is now becoming well recognized. However,
adequate administration of thromboprophylaxis regimens
does not seem to occur after total joint arthroplasty in a
large number of cases. The reasons for this appear complex,
involving surgeons’ poor awareness of the problem of
post-surgical thrombosis, their attitudes to guidelines,
concerns about causing bleeding, and the complexities of
anticoagulation with current agents. Simplifying therapy,
such as once-daily ﬁxed dosing, could change attitudes to
anticoagulant use and improve adherence to guidelines.
Newly developed, oral, ﬁxed-dose anticoagulants should
enable substantial improvement in thromboprophylaxis
usage, thereby improving patient outcomes. The primary
drawback of the new anticoagulants, particularly those with
alonghalf-life,isthelackofspeciﬁcantidotestoreversetheir
anticoagulant eﬀect [56]. Speciﬁc antidotes might be needed
in particular situations such as for overdose or emergency
surgery. However, this may not pertain to dabigatran and
rivaroxaban as they have relatively short half-lives (12–14
hoursand7–11hours,resp.)[45,53].Asoﬀ-labelprescribing
is not uncommon, there is a risk that new anticoagulants
licensed for thromboprophylaxis after THA or TKA will be
prescribed for unlicensed indications [57]. These current
challenges could be overcome by ﬁnding speciﬁc antidotes
and postapproval surveillance of oﬀ-label prescribing.
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